The PREEMIE Reauthorization Act of 2025 updates the existing Prematurity Research Expansion and Education for Mothers who deliver Infants Early (PREEMIE) statutory language to extend authorization through fiscal years 2025–2029, corrects a technical cross-reference from the 2018 reauthorization, and strengthens federal coordination by converting a discretionary HHS authority into a deadline-driven obligation to form an interagency working group.
The bill also directs HHS to contract with the National Academies of Sciences, Engineering, and Medicine to convene an expert committee quickly and produce, within two years, a consensus report that assesses the financial costs of prematurity, drivers of preterm birth rates, opportunities for earlier detection and post-discharge supports, and targeted research strategies—including precision medicine approaches—while also transmitting the underlying raw data to HHS and Congress. Those requirements create near-term deliverables but leave key implementation choices—funding, data-sharing protocols, and interagency roles—to HHS and appropriators.
At a Glance
What It Does
Amends the PREEMIE statute to extend the authorization period to FY2025–2029, fixes a drafting error in the 2018 reauthorization, converts a discretionary interagency process into a mandatory one with an 18‑month deadline, and orders the National Academies to convene a committee that must deliver a consensus report (plus raw data) within 24 months.
Who It Affects
Primary duties fall on HHS and its components (including agencies that run maternal and child health programs), the National Academies as contractor, state public‑health programs and neonatal care providers who supply data and operational detail, and researchers and payers who will use the report’s recommendations.
Why It Matters
The bill turns federal coordination from optional to required, sets a national evidence-gathering timetable, and raises expectations around data transparency and research priorities—moves that can reshape funding requests, program design, and data-sharing practices across health systems and state programs.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The Act does three things that matter on day one. First, it updates the original PREEMIE authorization so the program’s statutory authorization runs through fiscal year 2029 and corrects a numbering error in the 2018 reauthorization.
That is largely housekeeping but keeps the PREEMIE authority alive for committees and appropriators.
Second, it changes HHS’s role from optional to mandatory: instead of permitting HHS to ‘‘establish’’ an interagency working group, the statute now requires HHS to create that group within 18 months of enactment. That shifts interagency coordination from a soft recommendation to a tangible obligation, which will require HHS to decide membership, scope, and resourcing for a working group meant to improve federal alignment on prematurity research and education.Third, and most consequentially, the bill directs HHS to contract with the National Academies to convene a committee of maternal‑health experts.
The Academies must assemble the committee within 30 days, produce a consensus report within 24 months, and include in that report an assessment of the financial costs of prematurity (including NICU stays and long‑term family costs), factors driving preterm birth rates, and opportunities for earlier detection and public‑health supports. The statute also requires three specific analyses: targeted research strategies for drugs and interventions, a compilation of state and other best practices, and an examination of precision medicine and preventive approaches across the life course.
The National Academies must transmit the report and the raw data used to HHS and specified Congressional committees.Practically, the bill creates fast deadlines and sets a high bar for transparency: Congress expects a consensus report plus the underlying raw data it used. But the text does not appropriate money or lay out detailed data‑sharing protocols, so HHS will need to use contracting authorities, allocate budgetary resources, and address privacy and legal limits before full implementation.
The report’s findings—on costs, best practices, and research pathways—will likely inform future grant priorities, program guidance, and budget requests for maternal and neonatal health programs.
The Five Things You Need to Know
The bill amends 42 U.S.C. 247b–4f(e) to replace the former authorization window (fiscal years 2019–2023) with fiscal years 2025–2029.
Section 5(a) of the PREEMIE Reauthorization Act of 2018 is changed from permissive to mandatory: HHS must establish an interagency working group not later than 18 months after enactment.
The Secretary must enter into arrangements with the National Academies to convene a committee within 30 days of enactment and deliver a consensus report to HHS and three Congressional committees within 24 months.
The required report must include an assessment of the financial costs of premature birth (NICU stays, long‑term societal and family costs, and post‑discharge healthcare), factors influencing preterm rates, and opportunities for earlier detection and supports across settings.
The Academies’ required analysis must cover targeted research strategies to develop drugs/treatments, a review of State and other best practices for reducing prematurity, and an evaluation of precision medicine and preventive approaches beginning during pregnancy and across the life course.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Declares the Act’s short title as the "PREEMIE Reauthorization Act of 2025." This is purely formal but identifies the bill for statutory citation and cross‑referencing in later regulations and documents.
Extend authorization period; technical correction
Replaces the fiscal years referenced in the PREEMIE statute so the program is authorized through FY2025–2029. Practically, this preserves the program’s statutory authorization window for budgeting and oversight. The provision also makes a retroactive technical correction to a section reference from the 2018 reauthorization, treating that correction as if it were included in the 2018 law to avoid downstream drafting confusion in implementing regulations and grant documents.
Mandate to create an interagency working group
Alters Section 5(a) of the 2018 Act by replacing permissive language with a directive: HHS must establish an interagency working group within 18 months. The change forces HHS to formalize membership, reporting lines, and an initial charter; agencies with maternal and child health responsibilities (CDC, NIH, HRSA, CMS, etc.) will need to coordinate engagement. The statute is silent on staffing and funding, so the working group’s scope will depend on HHS decisions and available resources.
Contracting with the National Academies and committee convening
Requires the Secretary to enter into arrangements with the National Academies under which the Academies must convene a committee of maternal‑health experts within 30 days of enactment. That tight convening deadline pressures the contracting timeline and assumes available Academy capacity; the provision does not specify procurement details or a funding source, so HHS must use existing authorities and appropriations to meet the requirement.
Required report, raw data, and transmission deadlines
Specifies the report’s content: a cost assessment of prematurity (NICU and long‑term costs), factors affecting preterm birth rates, opportunities for earlier detection and public‑health support, and three mandated analyses (targeted research strategies, State best practices, and precision/ preventive approaches). The Academies must approve the report by consensus, include the raw data underlying their analysis, and transmit the report and data to HHS and relevant Congressional committees within 24 months. Those requirements create a high expectation for transparency and actionable analysis but raise immediate questions about de‑identification, HIPAA compliance, and data stewardship.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Mothers who deliver preterm infants and their families — the bill prioritizes study of NICU stays, post‑discharge costs, and supports that could translate into policy changes and program expansion to reduce financial and health burdens.
- Researchers and academic centers — the National Academies report and the requirement to include raw data could create a clearer national evidence base, identify priority research questions, and expand datasets useful for secondary analysis.
- State and local public‑health programs — the mandated review of State 'best practices' offers a pathway to validate and scale effective interventions and to secure federal guidance grounded in cross‑jurisdictional evidence.
- Neonatal care providers and NICUs — a focused analysis of treatments and interventions may identify evidence‑based protocols and research priorities that affect clinical practice and reimbursement negotiations.
- Payers and health systems — a rigorous cost assessment can inform value‑based payment models, coverage decisions, and investments in prevention and post‑discharge care that reduce long‑term costs.
Who Bears the Cost
- Department of Health and Human Services — HHS must convene the working group, manage contracting with the National Academies, and absorb administrative and coordination costs unless Congress appropriates new funds.
- National Academies / federal contractor costs — the Academies will incur convening and study expenses that HHS must fund through existing appropriations or a new obligation; tight deadlines increase marginal costs.
- Hospitals and NICUs — providers will likely supply data and operational detail for the study, creating staff time, record‑assembly, and potential compliance costs for sharing sensitive clinical data.
- State and local health departments — they may face requests to share programmatic data and to disseminate or implement recommended best practices, which can require staffing and budget adjustments.
- Patients and families — the raw‑data requirement increases the risk of privacy exposure and may create pressure to provide detailed post‑discharge cost and outcome information, raising consent and confidentiality burdens.
Key Issues
The Core Tension
The bill pushes for a fast, transparent, consensus‑driven national assessment to accelerate prevention and treatment of preterm birth, but that imperative collides with privacy and legal limits on clinical data, tight timelines and unfunded mandates for agencies, and the practical difficulty of achieving consensus across diverse technical and political stakeholders—so the law forces a trade‑off between speed/transparency and careful, resourced implementation.
Two implementation gaps matter. First, the bill demands rapid, data‑rich deliverables but does not appropriate money or establish specific data‑sharing protocols.
HHS will need to decide whether to use existing PREEMIE or HHS funds to pay the National Academies and to support the interagency working group; absent clear budgetary direction, meeting the 30‑day convening requirement and the 24‑month reporting deadline could force agencies to reallocate staff and slow other projects.
Second, the statute’s requirement that the National Academies include the raw data used to develop the report raises legal and practical issues. Clinical and claims data are subject to HIPAA, state privacy laws, and contractual limits; producing useful raw datasets will require robust de‑identification, data‑use agreements, and possibly limited or tiered access.
The bill also requires committee consensus approval and transmittal to Congressional committees, which increases the risk that a politically sensitive finding could be delayed or that stakeholders will push to control data release. Finally, converting an optional interagency mechanism into a mandatory one improves accountability in theory but risks creating a low‑capacity, unfunded body that accomplishes little unless HHS and appropriators fund it adequately and define clear deliverables and authority.
Operationally, the scope is broad—covering costs, clinical factors, prevention, precision medicine, and state practices—so choices about methodology (what counts as 'cost' or a 'best practice') will drive outcomes. Those methodological choices, combined with the raw‑data requirement and consensus approval rule, make the report’s content as dependent on process design as on empirical findings.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.